In a 69-year-old woman with dysuria and a urine culture growing Candida glabrata (10,000–250,000 colony‑forming units per milliliter) who has persistent vaginal itching despite a single 150 mg dose of fluconazole, should fluconazole be started empirically for a possible symptomatic Candida urinary tract infection, or should susceptibility testing be obtained and a vulvovaginal infection be evaluated first due to potential fluconazole resistance?

Do Not Start Fluconazole Empirically – Evaluate for Vulvovaginal Candidiasis First and Consider Non-Fluconazole Therapy

Given the persistent vaginal itching despite prior fluconazole, the isolation of Candida glabrata (which has intrinsic reduced susceptibility to fluconazole), and the low colony count with negative nitrites/bacteria, this patient most likely has vulvovaginal candidiasis rather than a true urinary tract infection, and fluconazole is the wrong choice for C. glabrata infection.

Clinical Reasoning: Distinguishing VVC from UTI

The clinical presentation strongly suggests vulvovaginal candidiasis (VVC) rather than Candida UTI:

• Persistent vaginal itching is the hallmark symptom of VVC 1
• Dysuria in VVC typically represents "external dysuria" from urine contacting inflamed vulvar tissue 1
• The urine culture showing C. glabrata 10,000-250,000 CFU/mL likely represents vaginal contamination of the urine specimen rather than true cystitis
• Negative nitrites and no bacteria argue against bacterial UTI
• The leukocyte esterase and WBCs are nonspecific and can occur with vaginal contamination 2

True symptomatic Candida cystitis typically presents with suprapubic pain, urgency, and frequency—not primarily vaginal itching 3, 2. Most candiduria represents asymptomatic colonization or catheter-associated colonization 3, 4.

The C. glabrata Problem: Fluconazole Resistance

This is critical: C. glabrata has intrinsic reduced susceptibility to fluconazole, and azole therapy is "frequently unsuccessful" 1. The IDSA guidelines explicitly state that C. glabrata is an exception to fluconazole responsiveness 1.

The patient's failure to respond to fluconazole 150 mg already demonstrates this resistance pattern. Starting more fluconazole would be futile and delay appropriate therapy.

Recommended Management Algorithm

Step 1: Perform Gynecologic Evaluation

• Obtain vaginal wet mount with KOH preparation to confirm yeast/hyphae and document normal pH (4.0-4.5) 1
• Look for vulvar edema, erythema, excoriation, and thick white discharge 1
• This confirms VVC diagnosis and distinguishes it from other causes of vaginal symptoms

Step 2: Obtain Susceptibility Testing

• Request antifungal susceptibility testing on the C. glabrata isolate 1
• This determines if fluconazole resistance is present (likely given clinical failure)
• Guides definitive therapy selection

Step 3: Initiate Appropriate Therapy for C. glabrata VVC

For C. glabrata vulvovaginitis unresponsive to oral azoles, use:

First-line: Intravaginal boric acid 600 mg in gelatin capsules daily for 14 days 1 (strong recommendation; must be compounded by pharmacist)

Alternatives:

• Nystatin intravaginal suppositories 100,000 units daily for 14 days 1
• Topical 17% flucytosine cream ± 3% amphotericin B cream daily for 14 days 1 (requires compounding)

Step 4: Address the "UTI" Question

If truly concerned about upper tract involvement (fever, flank pain, systemic symptoms):

• Renal imaging with ultrasound or CT to evaluate for pyelonephritis or fungus balls 2
• For confirmed Candida UTI with C. glabrata, amphotericin B deoxycholate is the treatment of choice since fluconazole is ineffective and echinocandins don't achieve adequate urinary levels 3, 4, 5, 6

However, this patient's presentation (vaginal itching, no systemic symptoms) does not warrant this evaluation.

Common Pitfalls to Avoid

1. Treating candiduria without symptoms: Asymptomatic candiduria does not require treatment except in neutropenic patients, very low-birth-weight infants, or those undergoing urologic procedures 3, 4

2. Using fluconazole for C. glabrata: This species has intrinsic resistance; empiric fluconazole will fail 1, 7

3. Assuming urine culture = UTI: Vaginal contamination is common, especially with concurrent VVC 2

4. Using echinocandins for urinary infections: These drugs achieve inadequate urine concentrations and are inappropriate for Candida UTI 3, 4, 5

Why This Matters for Morbidity and Quality of Life

Untreated or inadequately treated VVC causes significant morbidity through:

• Persistent vulvovaginal discomfort and pruritus
• Dyspareunia affecting sexual function and relationships
• Potential progression to recurrent VVC (≥4 episodes/year) requiring 6 months of suppressive therapy 1

Using the wrong antifungal (fluconazole for C. glabrata) prolongs suffering and may select for further resistance 1, 8. The patient has already failed one course of fluconazole—repeating this mistake delays appropriate topical therapy that actually works for C. glabrata 1, 9.